RANK‐RANKL signalling pathway contributes to disease progression in cutaneous angiosarcoma: a case report with an immunohistochemical review and in vitro experiments
RANK‐RANKL signalling pathway contributes to disease progression in cutaneous angiosarcoma: a case report with an immunohistochemical review and in vitro experiments
复制标题
RANK-RANKL信号通路促进皮肤血管肉瘤的疾病进展：免疫组织化学综述和体外实验的病例报告
DOI：
10.1111/jdv.16714
复制
发表时间：
2020
影响因子：
9.2
通讯作者：
Yanagi T.
中科院分区：
文献类型：
--
作者：
Maeda T.;Kitamura S.;Yanagi T.
RANK-RANKL信号通路促进皮肤血管肉瘤的疾病进展：一个免疫组织化学回顾和体外实验的病例报告。皮肤血管肉瘤（CASs）通常发生在老年人的头皮上。1已知CAS预后较差，需要有希望的治疗方法来改善预后。2,3由于我们一直在使用denosumab治疗化疗耐药的晚期CAS病例，denosumab是一种针对核因子κ b配体受体激活剂抑制剂（RANKL）的单克隆抑制剂，我们在此描述他的临床过程。(c)测定人脐静脉内皮细胞（HUVECs）、正常人真皮成纤维细胞（NHDF）和HAMON血管肉瘤细胞中RANK/RANKL蛋白的表达水平。[文章节选]
RANK-RANKL signalling pathway contributes to disease progression in cutaneous angiosarcoma: a case report with an immunohistochemical review and in vitro experiments To the Editor, Cutaneous angiosarcomas (CASs) typically arise on the scalp in the elderly. 1 CAS is known to have poor prognosis, and there is a need for promising treatments that improve the prognosis. 2, 3 As we have been treating a chemotherapy-resistant advanced CAS case through denosumab, a monoclonal inhibitor against receptor activator inhibitor of nuclear factor kappa-B ligand (RANKL), we herein describe his clinical course.(c) The expression levels of RANK/RANKL protein were assessed from human umbilical vein endothelial cells (HUVECs), normal human dermal fibroblasts (NHDF) and HAMON angiosarcoma cells.[Extracted from the article]